Powder: -20°C for 3 years | In solvent: -80°C for 1 year
TG003, a potent inhibitor of Clk1/Sty, exhibits inhibitory activity against Clk1 and Clk4 with IC50 values of 20 nM and 15 nM, respectively [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | 5 days | $ 59.00 | |
5 mg | 5 days | $ 98.00 | |
10 mg | 5 days | $ 162.00 | |
25 mg | 5 days | $ 336.00 | |
1 mL * 10 mM (in DMSO) | 5 days | $ 179.00 |
Description | TG003, a potent inhibitor of Clk1/Sty, exhibits inhibitory activity against Clk1 and Clk4 with IC50 values of 20 nM and 15 nM, respectively [1]. |
In vitro | TG003 demonstrates a potent inhibitory effect on Clk1/Sty and Clk4, with IC 50 values of 15–20 nM, and exhibits a lesser inhibition on Clk2 at 200 nM. It effectively inhibits SF2/ASF-dependent β-globin pre-mRNA splicing in vitro through the suppression of Clk-mediated phosphorylation. Additionally, TG003 reduces serine/arginine-rich protein phosphorylation, prevents the dissociation of nuclear speckles, and inhibits Clk1/Sty-dependent alternative splicing in mammalian cells [1]. Moreover, this small molecule drug enhances the endogenous expression of p53β and p53γ protein isoforms by modulating TP53 intron 9 alternative splicing [2]. |
In vivo | Intrathecal administration of TG003 (1-100 pM) or IC261 (0.1-1 nM) leads to a dose-dependent alleviation of mechanical allodynia and thermal hyperalgesia triggered by carrageenan or CFA [3]. |
Molecular Weight | 249.33 |
Formula | C13H15NO2S |
CAS No. | 719277-26-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
TG003 719277-26-6 inhibitor inhibit